Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Unselective histone deacetylase (HDAC) inhibitors are being explored as a novel therapy for lymphoid malignancies.
• The expression patterns of HDAC enzymes in various cancers, including lymphoid malignancies, are not well understood, limiting targeted treatment strategies.

Purpose of the Study:

• To investigate the expression of class I and class II HDACs in lymphoid malignancies.
• To determine the potential of HDACs, particularly HDAC6, as therapeutic targets in lymphoma.

Main Methods:

• Analysis of class I and class II HDAC expression in a panel of lymphoid cell lines and primary tumor tissue sections.
• Assessment of HDAC6 expression levels in different lymphoma subtypes and correlation with hyper-acetylated tubulin.
• Evaluation of sensitivity to the class I HDAC inhibitor MGCD0103 in cell lines with varying HDAC6 expression.

Main Results:

• Class I HDACs were highly expressed in all studied lymphoid cell lines and primary tumors, including reactive cells in the Hodgkin lymphoma (HL) microenvironment.
• HDAC6 expression was significantly reduced or absent in a majority of lymphoid cell lines (64%) and primary lymphoma tissues (93%), including diffuse large B-cell lymphoma and classical HL.
• Lymphoma cell lines with low HDAC6 expression exhibited aberrant hyper-acetylated tubulin and increased sensitivity to the HDAC inhibitor MGCD0103.

Conclusions:

• HDAC6 is infrequently expressed in primary lymphoma cases.
• The limited expression of HDAC6 suggests it may not be a primary therapeutic target for most lymphoid malignancies.
• Targeting class I HDACs warrants further investigation, as class I enzymes are broadly expressed in these cancers.